Quantcast

Latest Humanized antibody Stories

2011-01-04 07:00:00

ROCHESTER, N.Y., Jan. 4, 2011 /PRNewswire/ -- Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors. (Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO) VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D). It is the...

2010-12-07 04:00:00

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs. Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and...

2010-10-05 15:09:33

New method will simplify study and treatment of diseases Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them. In an international cooperation, scientists from the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now succeeded in developing a promising approach to solve this...

2010-10-04 06:00:00

INCLINE VILLAGE, Nev., Oct. 4 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the October 1, 2010 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as of September 15, 2010, the record date. As previously announced, the conversion rate for the Company's 2.00% Convertible Senior Notes due February 15, 2012 was adjusted to 140.571 shares of common stock per $1,000 principal amount or $7.11 per share. The...

2010-09-08 06:00:00

INCLINE VILLAGE, Nev., Sept. 8 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the Company's president and chief executive officer, will present at the following upcoming conferences. Rodman & Renshaw Annual Global Investment Conference Monday, September 13, 2010 4:30 p.m. Eastern time New York City Morgan Stanley Global Healthcare Unplugged Conference Tuesday, September 14, 2010 3:55 p.m. Eastern time...

2010-09-02 04:35:01

Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease. BAN2401 is the first monoclonal antibody to selectively bind, neutralize and eliminate soluble protofibrils, the toxic amyloid-beta aggregates thought to cause Alzheimer's disease. With this new treatment approach, it is...

2010-08-12 14:50:00

BURLINGAME, Calif., Aug. 12 /PRNewswire/ -- Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders. Apexigen was formed with exclusive rights to develop and commercialize therapeutic monoclonal antibodies derived from Epitomics RabMAb® (Rabbit Monoclonal Antibody)...

2010-08-11 07:00:00

INCLINE VILLAGE, Nev., Aug. 11 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that Christine Larson, the company's vice president and chief financial officer, will present at the 2010 Global Hunter Securities Healthcare Conference in Newport Beach, California on August 17, 2010 at 4:00 P.M. Pacific Time. To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company...

2010-07-01 13:52:00

BOSTON, July 1 /PRNewswire/ -- China PharmaHub Corp. ("PharmaHub"), announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. (OTC Bulletin Board: WRLC) of which it recently purchased a 77% interest. The management of World Wide Relics ("WWR") and PharmaHub are looking forward to the potential merger and are working diligently towards it. PharmaHub is...

2010-06-03 16:00:00

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will provide broad leadership to the Company and have primary responsibility for its operations and infrastructure, in particular the development and commercialization of YM's pipeline. "After the successful merger of Cytopia into YM and with the further support of our...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.